Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Analysts expect Winrevair to become a multi-billion-dollar product for Merck, which has been beefing up its portfolio of cardiovascular drugs to counter a looming hit to sales of its top-selling ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 10% in early trading, largely because of weaker ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, isn't doing enough to ensure that its pipeline of products remains robust ...